R&d and innovation
Homepage
/
Product Pipeline

R&D and Innovation

All categories

News Center

Viwit’s Levetiracetam Tablets Approved by FDA 2024-04-09 11:28:41
On April 5, 2024, Viwit Pharmaceuticals' Levetiracetam Tablets received an Approval Letter (#078869) from the U.S. Food and Drug Administration (FDA), marking Viwit's first approved oral solid dosage in the United States.
Viwit Pharmaceuticals' Mirabegron API Receives Official Approval by China NMPA 2024-01-26 11:09:29
On January 23, 2024, Viwit Pharmaceuticals received the "Notice of Approval of Application for Listing of Chemical APIs" issued by China National Medical Products Administration (NMPA) for its own proprietary active pharmaceutical ingredient (API) Mirabegron, developed independently. The issued registration number is Y20220000096, and the corresponding notice number is 2024YS00039.
Viwit Pharmaceuticals' Vildagliptin Tablets Receive Official Approval by China NMPA 2023-12-22 13:19:44
Viwit Pharmaceuticals is pleased to announce the acquisition of the Drug Registration Certificate (Certificate No: 2023S01974) from the National Medical Products Administration (NMPA) for a proprietary finished dosage form, Vildagliptin tablet. This signifies the official approval of this product in the Chinese market.
Viwit Pharmaceuticals' Lidocaine Injection Receives Official Approval by China NMPA 2023-12-19 11:25:05
On December 18, 2023, Viwit Pharmaceuticals received the "Drug Supplementary Application Approval Notice" (Notice No: 2023B06224) issued by the China National Medical Products Administration for a proprietary finished dosage form, Lidocaine Hydrochloride for Injection (5ml: 0.1g).
Viwit Pharmaceuticals' Vildagliptin API Receives Official Approval by China NMPA 2023-12-07 08:31:28
On November 30, 2023, Viwit Pharmaceuticals received the "Notice of Approval of Application for Listing of Chemical APIs" issued by National Medical Products Administration (NMPA) for its independently developed active pharmaceutical ingredient (API), Vildagliptin. The registration number is Y20210000619, and the notice number is 2023YS00803.
Viwit Pharmaceuticals' Aprepitant API Receives Official Approval by China NMPA 2023-10-31 15:33:57
On October 26, 2023, Viwit Pharmaceuticals received the "Notice of Approval of Application for Listing of Chemical APIs" issued by China National Medical Products Administration (NMPA) for the independently developed active pharmaceutical ingredient (API) Aprepitant. The registration number is Y20210000473, and the notice number is 2023YS00727.

Product Pipeline

Product Pipeline

Description:
Description:
Information

FDF：

Product Name

Main Indication

Clindamycin Phosphate Injection
4ml:0.6g, 2ml:0.3g

Antibacterials

Levofloxacin Hydrochloride Injection
5ml:0.5g, 5ml:0.3g

Antibacterials

Fleroxacin Injection
10ml:0.4g, 10ml:0.2g, 10ml:0.1g

Antibacterials

Azithromycin Lactobionate Injection
5ml:0.5g, 2.5ml:0.25g

Antibacterials

Cefoperazone Sodium and Sulbactam Sodium

for Injection  1.0g

Beta-Lactam Antibacterials

Ganciclovir Injection
20ml:0.25g

1. Cytomegalovirus retinitis in immunodeficiency patients (including AIDS patients)

2. Prevent cytomegalovirus infection that may occur in recipients of organ transplants

Pefloxacin Mesylate Injection
5ml:0.4g, 2ml:0.2g

Antiinfectives

Lidocaine Hydrochloride Injection
5ml:0.1g, 20ml:0.4g

Local anesthetics

Lidocaine hydrochloride injection(for solvent)
5ml:10mg, 2ml:4mg

Local anesthetics

Propyl Gallate Injection
5ml:60mg, 10ml:120mg

Anti-thrombotic drugs

Puerarin Injection
8ml:0.4g, 5ml:0.25g

Cerebrovascular and peripheral vasodilators

Marine Injection
5ml:0.6g

Hepatobiliary medication

Vitamin C Injection
5ml:0.5g, 2ml:0.25g, 2ml:0.1g

Scurrvy,various acute and chronic infectious diseases and purpura,chronic iron poisoning,idiopathic methemoglobinemia

Vitamin B12 Injection
1ml:1mg, 1ml:0.5mg, 1ml:0.25mg, 1ml:0.1mg, 1ml:0.05mg

Megaloblastic anemia,and also used for adjuvant treatment of neuritis

Lappaconitine Hydrobromide Injection
2ml:4mg

Moderate or higher pain

Piroxicam Injection
2ml:20mg

Symptomatic treatment for pain and swelling of various arthritis and soft tissue lesions

Aceglutamide Injection
2ml:100mg

Traumatic brain coma, coma caused by neurosurgery, liver coma and hemiplegia, high paraplegia, sequelae of polio, neurological headache and low back pain

Diazepam Injection
2ml:10mg

Hypnotics and Sedatives

API：

Product Name

Main Indication

Varenicline Tartrate

Smoking cessation drugs for adults

Aprepitant

Prevent acute and delayed nausea and vomiting caused by chemotherapy

Fosaprepitant Dimeglumine

Chemotherapy antiemetics

Vildagliptin

Type 2 diabetes

Efinaconazole

Topical triazole antifungal

Gadoterate Meglumine

MRI contrast agent

Gadobutrol

MRI contrast agent

Mirabegron

Symptomatic treatment of urgency, frequency and/or urge incontinence in adults with overactive bladder (OAB)

Luliconazole

Fungal Infections

Atazanavir sulfate

Combination for HIV-1 infection

 

 

Scan the QR code to read on your phone

search
Confirm
Close
About Us
Company Introduction Corporate History Business Introduction Corporate Governance Company Culture Corporate Honors Viwit Family Media Center Video
R&D and Innovation
R&D Innovation Product Pipeline Achievements
Products
Drug Products Biologics APIs Intermediates Boranes OLED Materials
Innovation
CDMO Project Collaboration In-/Out-Licensing Joint Venture
Sustainable
EHS Energy Quality Supplier
News Center
In 2024 In 2023 In 2022 In 2021 In 2020 In 2019 In 2018 In 2017 In 2016
Join Us
Talent Philosophy Talent Development Salary and Benefits Campus Recruiting Social Recruitment
Contact Us
Online Message Contact Us
News Center
dp EN
dp 中文

wz

wz